הכינוס השביעי של

האגודה הישראלית לתרפיה גנטית ותאית (איתג"ת)   

       בחסות האגודה לקידום מחקר הסוכרת בישראל (IASD)

                                               יום ד',  5 במאי 2010, כ"א אייר תש"ע

                                     במרכז הרפואי ע"ש שיבא, תל השומר, רמת גן, ישראל

                                                          אולם סוראסקי

תוכנית מדעית

להורדת התכנית לחץ כאן

מרצים מוזמנים:

Reprogramming liver cells into insulin-producing cells by pancreatic transcription factors
Li-Jun Yang, University of Florida, Gainsville, FL, USA

Gene transfer to induce cellular reprogramming for the treatment of diabetes
Mark Kay, Stanford, CA, USA

Reprogramming into pancreatic beta cells  based on developmental cues, converting alpha to beta cells
Patrick Collombat, INSERM, Nice, France

AAV vectors for gene therapy of the brain in lysosomal storage diseases
Jean Michel Heard, Institute Pasteur, INSERM, Paris, France

Ex-vivo expansion of adult human pancreatic islet beta cells
Shimon Efrat, Tel-Aviv University, Tel-Aviv, Israel

Delineating the molecular mechanisms regulating chromatin protein dynamics in embryonic stem cells
Eran Meshorer, The Hebrew University, Jerusalem, Israel

hESC – from bench to patient 
Benjamin Reubinoff,  Hadassah University Hospital, Jerusalem, Israel

Differentiated mesenchymal stem cells rescue sciatic nerve injury in rats
Daniel Offen, Tel-Aviv University, Tel-Aviv, Israel & and Rabin Medical Center, Petach Tikva, Israel

Targeting CEACAM1 in adoptive TIL transfer in melanoma
Gal Markel, Sheba Medical Center, Ramat-Gan, Israel and Tel-Aviv University, Tel-Aviv, Israel

Identification and prospective isolation of novel human renal stem/progenitor populations from normal and cancerous kidney tissue
Benjamin Dekel, Sheba Medical Center, Ramat-Gan, Israel and Tel Aviv University, Tel-Aviv, Israel

Engineering cell platforms for cardiovascular regeneration
Marcelle Machluf, Technion-IIT, Haifa, Israel

Dynamic interactions between the nervous and immune systems with the microenvironment, regulate normal and leukemic human stem cells
Tsvee Lapidot, Weizmann Institute of Science, Rehovot, Israel

Clinical and future application of autologous multipotential mesenchymal stromal stem cells for the treatment of neurological diseases

Shimon Slavin, International Center for Cell Therapy and Cancer Immunotherapy (CTCI), Tel-Aviv, Israel